PIAE risk minimized by additional treatment

Article

Treatment of blepharitis before injection, avoidance of subconjunctival anaesthesia and topical antibiotic administration immediately after injection all contribute to minimizing the risk of contracting post-intravitreal anti-VEGF endophthalmitis (PIAE).

Treatment of blepharitis before injection, avoidance of subconjunctival anaesthesia and topical antibiotic administration immediately after injection all contribute to minimizing the risk of contracting post-intravitreal anti-VEGF endophthalmitis (PIAE), claims a study in Eye.

Dr D. A. Lyall et al., Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK, conducted a prospective observational case control study on 47 patients with PIAE.

Patients were identified through the British Ophthalmological Surveillance Unit from January 2009 to March 2010 and data was gathered at diagnosis and at six months follow-up. The measures included patient demographics, intravitreal injection details, pre- and post-injection management, visual acuity, clinical features and management of PIAE, causative organisms and clinical outcomes. All subjects were compared to 200 control participants from 10 control centres to determine potential risk factors.

Positive microbiology culture was discovered in 59.6% of patients and the majority of causative organisms were Gram positive. The significant risk factors included failure to administer topical antibiotics immediately after the injection, blepharitis, subconjunctival anaesthesia, patient squeezing during the injection and failure to administer topical antibiotics before anti-VEGF injection.

The abstract can be viewed here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.